Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tavapadon

Generic Name: Tavapadon

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆F_₃N_₃O_₃

CAS Number: 1643489-24-0

Unique Ingredient Identifier: PT4P8MJP8L

Overview

Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Phase 1

Recruiting

Posted: 2025/03/26

Sponsor:AbbVie

ID:NCT06895356

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Phase 1

Completed

Posted: 2022/11/09

Sponsor:Cerevel Therapeutics...

ID:NCT05610189

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Posted: 2022/10/17

Sponsor:Cerevel Therapeutics...

ID:NCT05581823

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase 1

Completed

Posted: 2022/06/03

Sponsor:Cerevel Therapeutics...

ID:NCT05404529

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Phase 1

Completed

Posted: 2022/06/03

Sponsor:Cerevel Therapeutics...

ID:NCT05404542

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Tavapadon Shows Promise in Phase 3 Trials for Parkinson's Disease with Improved Motor Function and Safety Profile

2 months ago

The TEMPO-1 and TEMPO-2 trials demonstrated that tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor function in newly diagnosed Parkinson's disease patients compared to placebo.

AbbVie's Skyrizi and Rinvoq Gain Market Share as Company Navigates Post-Humira Landscape

4 months ago

AbbVie reports significant market penetration for Skyrizi and Rinvoq in IBD indications, capturing approximately 50% market share in Crohn's disease and ulcerative colitis treatment spaces.

AbbVie Reassesses Emraclidine's Future After Phase II Schizophrenia Trial Failures

5 months ago

AbbVie's emraclidine failed to meet primary endpoints in Phase II trials for schizophrenia, leading to a $3.5 billion impairment charge and a reevaluation of its development path.

Key Advances in Neuromuscular and Movement Disorder Treatments Highlighted in 2024

5 months ago

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach.

AbbVie's Tavapadon Shows Positive Phase 3 Results for Parkinson's Disease

6 months ago

AbbVie's tavapadon demonstrated significant improvement over placebo in a Phase 3 trial (TEMPO-2) for Parkinson's disease, enhancing patients' motor skills and daily task performance.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy